ClinicalTrials.gg
TerminatedNCT03923010Updated Sep 1, 2021

A Study of Itraconazole in the Management of Superficial Fungal Infections in India

A Phase 4 interventional study of Itraconazole in Mycoses, sponsored by Janssen Research & Development, LLC. Terminated at 4 sites in India. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-09-01.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Prevention

Why this study was terminated
Further recruitment not possible due to COVID 19 impact. Hence a decision to close study was taken by the sponsor in Aug 2020

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to estimate the proportion of participants prescribed itraconazole for Tinea cruris or Tinea corporis who have clinical response after 7 days of treatment.

02

Conditions studied

  • Mycoses

Browse trials for

03

In context

Mycoses

260 studies on the registry are indexed under Mycoses; 37 are open to participants now.

This study's enrollment of 40 is below the median of 68 across 164 interventional studies indexed under Mycoses.

Browse Mycoses studies →

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically diagnosed with Tinea cruris or Tinea corporis with or without history of treatment
  • Are prescribed itraconazole at 200 milligram/day orally for the treatment of T. cruris or T. corporis and taken once a day
  • A woman of must have a negative highly sensitive serum (beta human chorionic gonadotropin [beta hCG]) at screening on Day -3 to 0 before start of study drug
  • A woman must be (a) not of childbearing potential (b) of childbearing potential and: Practicing a highly effective method of (failure rate of less than [\<] 1 percentage [%] per year when used consistently and correctly) and agrees to remain on a highly effective method while receiving study drug and until 30 days after last dose (that is, the end of relevant systemic exposure)
  • A male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person. A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum 90 days after receiving the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • History of ventricular dysfunction such as congestive heart failure (CHF) or receiving treatment for CHF, liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances at any time prior to the start of study
  • Known achlorhydria or on treatment of gastric acidity
  • Presence of other dermatoses, example. psoriasis, seborrhoeic or atopic dermatitis
  • Infected with organism with known or established resistance to itraconazole
  • Co-existing fungal infection of other body area
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Itraconazole

    Participants with Tinea cruris or Tinea corporis infection that have been prescribed itraconazole 200 milligram (mg) daily by their treating physician will be enrolled in this study. Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.

    Drug: Itraconazole

Interventions

  • Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.

    Also known as: JNJ-16269994

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Clinical Response

    Percentage of participants with clinical response will be reported. Assessment of clinical response will be done by using Investigator Global Evaluation tool based on the signs and symptoms and clinical improvement scores. The percentage of clinical improvement will be measured at the score ranging from 1 to 5 where Score 1: Healed (absence of signs and symptoms), Score 2: Markedly improved (greater than \[\>\] 50 percentage \[%\] clinical improvement), Score 3: Considerable residual lesion (less than \[\<\] 50% clinical improvement), Score 4: No change (same as baseline), and Score 5: Worse (deterioration from baseline). Clinical response will be defined as having Scores 1 or 2 (healed or markedly improved).

    Time frame: Day 7 (End of Treatment)

Secondary outcomes

  1. Percentage of Participants who Have Mycological Cure

    Percentage of participants who have mycological cure will be reported. Mycological cure is defined as both culture and microscopy negative to causative fungi.

    Time frame: Day 14

  2. Plasma Concentrations of Itraconazole and Hydroxy-Itraconazole

    Plasma concentrations of itraconazole and hydroxy-itraconazole will be measured.

    Time frame: Days 7 and 14: Pre-dose, 2 and 4.5 hours

  3. Baseline Minimum Inhibitory Concentration (MIC) of Itraconazole

    Minimum inhibitory concentration of itraconazole toward fungal pathogens will be determined.

    Time frame: Baseline (Day 0)

  4. Percentage of Participants with Clinical Response

    Percentage of participants with clinical response will be reported. Assessment of clinical response will be done by using Investigator Global Evaluation tool based on the signs and symptoms and clinical improvement scores. The percentage of clinical improvement will be measured at the score ranging from 1 to 5 where Score 1: Healed (Absence of signs and symptoms), Score 2: Markedly improved (greater than \[\>\] 50 percentage \[%\] clinical improvement), Score 3: Considerable residual lesion (less than \[\<\] 50% clinical improvement), Score 4: No change (same as baseline), and Score 5: Worse (deterioration from baseline). Clinical response will be defined as having Scores 1 or 2 (healed or markedly improved).

    Time frame: Day 14

07

Study locations

4 sites
  • Post Graduate Institute of Medical Education & Research (PGIMER)
    Chandigarh, 160012, India
  • Sri Ramachandra Medical Centre
    Chennai, India
  • Yenepoya Medical College
    Mangalore, 575018, India
  • Lata Mangeshkar Hospital
    Nagpur, 440001, India
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Mar 2020, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2019
First posted
Apr 22, 2019
StartActual
Aug 6, 2019
Primary completionActual
Mar 25, 2020
CompletionActual
Mar 27, 2020
Last update
Sep 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03923010
Responsible party
Sponsor
First posted
Apr 22, 2019
Start date
Aug 6, 2019
Primary completion
Mar 25, 2020
Completion
Mar 27, 2020
Last update
Sep 1, 2021

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itraconazole

Start the discussion